Phase II randomised control feasibility trial of a nutrition and physical activity intervention after radical prostatectomy for prostate cancer.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
06 11 2019
Historique:
entrez: 9 11 2019
pubmed: 9 11 2019
medline: 27 10 2020
Statut: epublish

Résumé

Dietary factors and physical activity may alter prostate cancer progression. We explored the feasibility of lifestyle interventions following radical prostatectomy for localised prostate cancer. Patients were recruited into a presurgical observational cohort; following radical prostatectomy, they were offered randomisation into a 2×3 factorial randomised controlled trial (RCT). A single National Health Service trust in the South West of England, UK. Those with localised prostate cancer and listed for radical prostatectomy were invited to participate. Random allocation was performed by the Bristol Randomised Trial Collaboration via an online system. Men were randomised into both a modified nutrition group (either increased vegetable and fruit, and reduced dairy milk; or lycopene supplementation; or control) and a physical activity group (brisk walking or control) for 6 months. Only the trial statistician was blind to allocations. Primary outcomes were measures of feasibility: randomisation rates and intervention adherence at 6 months. Collected at trial baseline, three and six months, with daily adherence reported throughout. Our intended adherence rate was 75% or above, the threshold for acceptable adherence was 90%. 108 men entered the presurgical cohort, and 81 were randomised into the postsurgical RCT (randomisation rate: 93.1%) and 75 completed the trial. Of 25 men in the nutrition intervention, 10 (40.0%; 95% CI 23.4% to 59.3%) adhered to the fruit and vegetable recommendations and 18 (72.0%; 95% CI 52.4% to 85.7%) to reduced dairy intake. Adherence to lycopene (n=28), was 78.6% (95% CI 60.5% to 89.8%), while 21/39 adhered to the walking intervention (53.8%; 95% CI 38.6% to 68.4%). Most men were followed up at 6 months (75/81; 92.6%). Three 'possibly related' adverse events were indigestion, abdominal bloating and knee pain. Interventions were deemed feasible, with high randomisation rates and generally good adherence. A definitive RCT is proposed. ISRCTN 99048944.

Identifiants

pubmed: 31699723
pii: bmjopen-2019-029480
doi: 10.1136/bmjopen-2019-029480
pmc: PMC6858112
doi:

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e029480

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Br J Cancer. 2012 Jun 26;107(1):201-6
pubmed: 22644301
Cancer Causes Control. 2006 Mar;17(2):199-208
pubmed: 16425098
Curr Opin Urol. 2006 May;16(3):132-7
pubmed: 16679848
Br J Cancer. 2013 Jun 11;108(11):2407-12
pubmed: 23695026
Int J Cancer. 2017 May 1;140(9):2060-2069
pubmed: 28187509
Am J Clin Nutr. 2010 Jan;91(1):106-14
pubmed: 19889820
Curr Oncol. 2017 Aug;24(4):e290-e315
pubmed: 28874900
Int J Cancer. 2015 Sep 15;137(6):1509-15
pubmed: 25761662
Cancer Causes Control. 2013 Jun;24(6):1119-28
pubmed: 23519639
BMC Cancer. 2015 Oct 15;15:710
pubmed: 26471791
J Clin Oncol. 2005 Aug 20;23(24):5814-30
pubmed: 16043830
Cancer Causes Control. 2017 Apr;28(4):319-329
pubmed: 28220328
JAMA. 2011 Jan 5;305(1):50-8
pubmed: 21205966
J Clin Oncol. 2007 Jul 1;25(19):2709-18
pubmed: 17602076
Am J Epidemiol. 1985 Jul;122(1):51-65
pubmed: 4014201
Trials. 2016 Mar 07;17(1):123
pubmed: 26948468
Trials. 2017 Mar 7;18(1):106
pubmed: 28264695
Cancer Causes Control. 2015 Nov;26(11):1521-50
pubmed: 26354897
Nutr Res Rev. 2004 Jun;17(1):5-22
pubmed: 19079912
BMJ Open. 2017 Oct 8;7(10):e018015
pubmed: 28993394
Iran J Public Health. 2016 Dec;45(12):1558-1567
pubmed: 28053921

Auteurs

Lucy E Hackshaw-McGeagh (LE)

National Institute for Health Research (NIHR) Biomedical Research Centre (Nutrition Theme), University of Bristol, Bristol, UK.

Chris Penfold (C)

National Institute for Health Research (NIHR) Biomedical Research Centre (Surgical Innovation Theme), Musculoskeletal Research Unit, University of Bristol, Bristol, UK.

Ellie Shingler (E)

National Institute for Health Research (NIHR) Biomedical Research Centre (Nutrition Theme), University of Bristol, Bristol, UK.

Luke A Robles (LA)

Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK.
MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

Claire M Perks (CM)

Bristol Medical School: Translational Health Sciences, University of Bristol, Bristol, UK.

Jeff M P Holly (JMP)

Bristol Medical School: Translational Health Sciences, University of Bristol, Bristol, UK.

Edward Rowe (E)

Bristol Urology Institute, Department of Urology, North Bristol NHS Trust, Bristol, UK.

Anthony Koupparis (A)

Bristol Urology Institute, Department of Urology, North Bristol NHS Trust, Bristol, UK.

Amit Bahl (A)

Bristol Haematology and Oncology Centre, University Hospitals Bristol, Bristol, UK.

Raj Persad (R)

Bristol Urology Institute, Department of Urology, North Bristol NHS Trust, Bristol, UK.

Constance Shiridzinomwa (C)

Clinical Research Centre, North Bristol NHS Trust, Bristol, UK.

Lyndsey Johnson (L)

Clinical Research Centre, North Bristol NHS Trust, Bristol, UK.

Kalina M Biernacka (KM)

Bristol Medical School: Translational Health Sciences, University of Bristol, Bristol, UK.

Aleksandra Frankow (A)

Bristol Medical School: Translational Health Sciences, University of Bristol, Bristol, UK.

Jayne V Woodside (JV)

Institute for Global Food Security, Queens University Belfast, Belfast, UK.

Sarah Gilchrist (S)

Institute for Global Food Security, Queens University Belfast, Belfast, UK.

Jon Oxley (J)

Department of Cellular Pathology, North Bristol NHS Trust, Bristol, UK.

Paul Abrams (P)

Bristol Urology Institute, Department of Urology, North Bristol NHS Trust, Bristol, UK.

J Athene Lane (JA)

Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK athene.lane@bristol.ac.uk.

Richard M Martin (RM)

Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH